Bismuth-Metronidazole Triple Therapy for H. Pylori First-line Treatment
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This randomized controlled clinical trial will compare the eradication efficacy of
bismuth-metronidazole triple therapy (PPI+bismuth+ metronidazole) with that of
bismuth-metronidazole quadruple therapy (PPI+bismuth+ metronidazole+ amoxicillin) for
Helicobacter pylori first-line treatment. The completion of this trial will expand new
therapy for the treatment of Helicobacter pylori, which can not only ensure clinical
efficacy, but also reduce the use of antibiotics.